Q1 2020 Ultimovacs ASA Earnings Call Transcript
Good morning, and welcome to this first-quarter 2020 presentation from Ultimovacs. We are streaming from an auditorium in the Oslo Cancer Cluster building.
What I can say is that in the first quarter, the main focus of the company have been to start-up the two trials, the INITIUM trial, and the NIPU trial. We will go through the details about those trials later. And everything that we can control in the startup process for those trials has gone according to the plan. But then as you all know, factors have come in that affect us and that we cannot control.
We will, in this presentation, go through the consequences and what we expect from the trials and in which way they will -- the COVID-19 situation, will affect us. We expected and planned for starting up both INITIUM and the NIPU trial at the end of first quarter, and that was delayed primarily because the hospitals decided that they were unable to perform clinical trials in the situation that they were in in the beginning of March.
However, the hospitals have now opened
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
